Xoma's Novartis Deal Distracts From Gevokizumab Flop
This article was originally published in Scrip
Executive Summary
Xoma Corp.'s stock returned above $1 per share on Oct. 1 after the company revealed a new preclinical immuno-oncology collaboration with Novartis, which gives the antibody therapeutics developer enough cash to fund early-stage internal programs through 2017.